SEER前列腺癌主动监测/观察等待数据库:机会与局限
该研究全面描述了新发布的SEER前列腺癌伴观察等待(WW)数据集,该数据集纳入2010–2015年18个SEER登记处新诊断的前列腺癌患者,旨在分析主动监测(AS)/观察等待(WW)的趋势。仅46%病例具有完整的基本癌症特征数据用于风险分层;数据集无法区分WW与AS,且缺失数据量不容忽视,可能导致潜在偏倚。
要点
- SEER前列腺癌伴WW数据集可分析AS/WW趋势,但仅46%病例有完整风险分层数据。
- 缺失数据导致的排除数据集与多重插补数据集在所有变量分布上均显著不同(p<0.001)。
- 该数据集无法区分观察等待(WW)与主动监测(AS),为固有局限。
核心结论
- 该数据集为描述前列腺癌治疗趋势(包括AS/WW)提供了新方法,但缺失数据量不容忽视,处理不当可导致潜在偏倚。
研究设计与样本
- 基于人群的流行病学登记研究,数据来自2010–2015年18个SEER登记处新诊断的前列腺癌患者。
主要发现
- 仅46%病例具有完整的基本癌症特征数据用于风险分层。
临床怎么用
- 利用该数据集分析AS/WW趋势时,需充分认识并妥善处理缺失数据,以避免偏倚。
- 解读结果时应注意到数据集无法区分WW与AS。
局限性
- 数据集无法区分观察等待(WW)与主动监测(AS)。
- 缺失数据量大,仅46%病例具有完整风险分层数据,可能导致偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Active surveillance (AS)/watchful waiting (WW) strategy for localized prostate cancer (PCa) is increasingly and broadly endorsed as a preferred option for initial treatment of men with very low- and low-risk PCa, but outcomes can be difficult to analyze in traditional, population-based registries. The recently released Surveillance, Epidemiology, and End Results (SEER) Prostate with WW dataset provides an opportunity to understand national patterns and trends in AS/WW, but the data source itself has not been well described. OBJECTIVE: To provide a comprehensive description of this dataset and investigate possible biases due to missing data. DESIGN, SETTING, AND PARTICIPANTS: The SEER is a population-based epidemiologic registry in the USA. Newly diagnosed PCa patient data were collected from 18 SEER registries between 2010 and 2015, with inclusion of a new treatment variable for AS/WW. We identified 316 724 patients in the entire cohort and 257 060 men with clinically localized PCa (T1-2N0M0). INTERVENTION: Various primary treatments for PCa. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The degree of missing data for each variable was measured. In order to investigate possible bias due to missing data for cancer characterization, we compared two versions of the data: one that excluded cases with missing data and one dataset generated applying multiple imputations. RESULTS AND LIMITATIONS: Only 46% of cases had complete data on basic cancer characteristics for risk stratification. The excluded dataset (N=118 821) differed significantly from the multiple imputation dataset (N=257 060) in the distribution of every reported variable (all p<0.001). The dataset does not distinguish WW from AS, which is a limitation. CONCLUSIONS: While the SEER Prostate with WW dataset offers a new method to describe treatment trends for men with PCa, including the use of AS/WW, the amount of missing data should not be ignored. PATIENT SUMMARY: While the Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting dataset offers a new method to describe treatment trends for men with prostate cancer, including the use of active surveillance, it has a significant amount of missing data, which can be a source of potential bias if not addressed properly.
引用
- Jeong CW, Washington SL, Herlemann A, et al. The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. Eur Urol. 2020. PMID: 31980309. doi:10.1016/j.eururo.2020.01.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。